ORCID "0000-0001-9636-4113" Makale Koleksiyonu için listeleme
-
Quality of life assessment with EORTC QLQ in patients with multiple myeloma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Koç Erol, İklil Nur; Arslan, Zeynep Ece; Tay, Zekiye Nur; Tuncer, Elif Nur; Sevindik, Ömür Gökmen (Galenos Publishing House, 2022)Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM). With the aid of the EORTC ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ... -
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Mutlu, Yaşa Gül; Yiğit Kaya, Süreyya; Maral, Senem; Melek, Elif; Başlar, Zafer; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Frontiers Media SA, 2023)Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific ... -
Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas?
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Çakır, Aslı; Canöz, Özlem; Erol, Cengiz; Sevindik, Ömür Gökmen (AVES, 2023)Objective: Surgical excisional biopsy is accepted as the standard of care approach in the diagnosis of lymphomas. Financial issues related to the increased cost and the invasive nature of the procedure forced physicians ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Yiğit Kaya, Süreyya; Mutlu, Yaşa Gül; Malkan, Ümit Yavuz; Mehtap, Özgür; Keklik Karadağ, Fatma; Korkmaz, Gülten; Elverdi, Tuğrul; Saydam, Güray; Özet, Gülsüm; Ar, Muhlis Cem; Melek, Elif; Maral, Senem; Kaynar, Leylagül; Sevindik, Ömür Gökmen (2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ... -
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma
Gemici, Aliihsan; Bilgen, Hülya; Erdoğan, Cem; Kansu, Abdullah; Olmuşçelik, Oktay; Beköz, Hüseyin Saffet; Dinleyici, Rümeysa; Mert, Ali; Sevindik, Ömür Gökmen (Tübitak Scientific & Technical Research Council Turkey, 2020)Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was ... -
Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
Karakuş, Volkan; Maral, Senem; Kaya, Egemen; Gemici, Aliihsan; Dere, Yelda; Sevindik, Ömür Gökmen (Kare Publishing, 2022)OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of ... -
Tocilizumab treatment in severe COVID-19: A multicenter retrospective study with matched controls
Mert, Ali; Vahaboğlu, Haluk; Arslan, Ferhat; Batirel, Ayşe; Saraçoğlu, Kemal Tolga; Baştuğ, Aliye; Çağatay, Atahan; Irmak, İlim; Telli Dizman, Gülçin; Ertenli, İhsan; Altunal, Lütfiye Nilsun; Ertürk Şengel, Buket; Bayram, Mehmet; Omma, Ahmet; Amikishiyev, Shirkhan; Aypak, Adalet; Bes, Cemal; Bölükçü, Sibel; İçten, Sacit; Topeli, Arzu; Bektaş, Murat; Arslan, Birsen Yiğit; Öztürk, Sinan; Çomoğlu, Şenol; Aydın, Selda; Küçükşahin, Orhan; İçaçan, Ozan Cemal; İnce, Burak; Aghamuradov, Sarvan; Yalçın Mutlu, Melek; Şimşek, Funda; Emre, Salih; Üstün, Cemal; Ergen, Pınar; Aydın, Özlem; Koç, Meliha Meriç; Sevindik, Ömür Gökmen; Odabaşı, Zekaver; Korten, Volkan; Bodur, Hürrem; Güner, Rahmet; Ünal, Serhat; Koçak, Mehmet; Gül, Ahmet (Springer Heidelberg, 2022)Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation syndrome (MAS). Elevated levels of IL-6 were ... -
What are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma?
Solmaz, Şerife; Acar, Celal; Seyhanlı, Ahmet; Sevindik, Ömür Gökmen; Pişkin, Özden; Özcan, Mehmet Ali; Demirkan, Fatih; Ündar, Bülent; Alacacıoğlu, İnci; Özsan, Güner Hayri (Wolters Kluwer Medknow Publications, 2020)Introduction: High-dose chemotherapy (HDC) and autologous stem cell transplantation(ASCT) still remains in the treatment of myeloma patients even during the period of new agents. Materials and Methods: We analysed the ...